Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in ESR1 and PIK3CA from ctDNA were assayed in clinical trial samples from ER+ metastatic breast cancer patients randomized either to the SERD fulvestrant or fulvestrant plus a pan-PI3K inhibitor. ESR1 mutations are present in 37% of baseline samples and are enriched in patients with luminal A and PIK3CA -mutated tumours. ESR1 mutations are often polyclonal and longitudinal analysis shows distinct clones exhibiting divergent behaviour over time. ESR1 mutation allele frequency does not show a consistent pattern of increases during fulvestrant treatment, and progression-free survival is not different in patients with ESR1 mutations compared with wild-type patients. ESR1 mutations are not associated with clinical resistance to fulvestrant in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The gain-of-function ERα LBD mutations are frequently found in metastatic endocrine-resistant breast cancers (Jeselsohn et al., 2014; Robinson et al., 2013; Spoerke et al., 2016; Toy et al., 2013; Zhang et al., 1997) and recruit elevated levels of the SRC coactivators to EREs (Gates et al., 2018).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Spoerke et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“Patients whose tissue was collected after receiving AI therapy shown on the left (21), and those whose tissue was collected before AI”
BackgroundThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Research works printed but not linked: 1
- Krop, I. E. et al. Phase 2 randomised study of the PI3-kinase inhibitor pictilisib plus fulvestrant versus placebo plus fulvestrant in patients with oestrogen receptor-positive, aromatase inhibitor-resistant advanced or metastatic breast cancer: the FERGI trial. Lancet Oncol (in the press).
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets
Liang, Y., Zhang, H., Song, X., & Yang, Q. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.012 · Cited by 992
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996
“This finding broadens the data in ESR1-mutant tumors that indicate that multiple distinct ESR1 resistance mutations can coexist in different drug-resistant cell populations, all subclonally, in post-endocrine therapy patients (Spoerke et al., 2016).”
BackgroundBaselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Epigenetic mechanisms in breast cancer therapy and resistance
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 458
Brett, J. O., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01462-3 · Cited by 414
“For example, the FERGI trial was retrospectively analyzed to determine how ESR1-MUT status affects response to fulvestrant [49].”
MethodO’Leary, B., Hrebien, S., Morden, J. P., Beaney, M., Fribbens, C., Huang, X., Liu, Y., Bartlett, C. H., Koehler, M., Cristofanilli, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03215-x · Cited by 414
Sinn, B. V., Fu, C., Lau, R., Litton, J., Tsai, T.-H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0111-0 · Cited by 354
ESR1 mutations in breast cancer
Dustin, D., Gu, G., & Fuqua, S. A. W. (2019) · Cancer · doi:10.1002/cncr.32345 · Cited by 306
“also confirmed that ESR1 mutations are frequently polyclonal.(9,28,34-37) Survival analyses showed that pa-”
BackgroundResultInfluentialCancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P., Kelly, L. M., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 270
“Examples of currently described public neoantigens include KRAS G12D/G12V, collectively found in 60-70% of pancreatic adenocarcinomas and 20-30% of colorectal cancers (58), and PIK3CA H1047L, detected in about 5% of metastatic breast cancers (59, 60).”
BackgroundAllele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Jeselsohn, R., Bergholz, J. S., Pun, M., Cornwell, M., Liu, W., Nardone, A., Xiao, T., Li, W., Qiu, X., Buchwalter, G., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.004 · Cited by 276
“Moreover, the ESR1 LBD mutations are prognostic of poor outcomes in patients with metastatic disease (Chandarlapaty et al., 2016; Spoerke et al., 2016).”
Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Duso, B. A., & Curigliano, G. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-24100-1_2 · Cited by 246
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 214
Estrogen Receptor Signaling in Breast Cancer
Miziak, P., Baran, M., Błaszczak, E., Przybyszewska-Podstawka, A., Kałafut, J., Smok-Kalwat, J., Dmoszyńska-Graniczka, M., Kiełbus, M., & Stepulak, A. (2023) · Cancers · doi:10.3390/cancers15194689 · Cited by 207
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L., & Chandarlapaty, S. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0001-z · Cited by 216
A Review of Fulvestrant in Breast Cancer
Nathan, M. R., & Schmid, P. (2017) · Oncology and Therapy · doi:10.1007/s40487-017-0046-2 · Cited by 204
“It seems intuitive that luminal A cancers should have a greater frequency of ESR1 mutations, as they are likely to have been exposed to several lines of aromatase inhibitors over a longer time course than other breast cancer subtypes [39].”
BackgroundSelf-citationFirst-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
Bidard, F.-C., Mayer, E. L., Park, Y. H., Janni, W., Ma, C., Cristofanilli, M., Bianchini, G., Kalinsky, K., Iwata, H., Chia, S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502929 · Cited by 178
Tumor Evolution as a Therapeutic Target
Amirouchene-Angelozzi, N., Swanton, C., & Bardelli, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0343 · Cited by 194
“Similar observations have been reported for patients with both breast (21) and lung cancers (22).”
ResultHerzog, S. K., & Fuqua, S. A. W. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01564-x · Cited by 178
Brown, D., Smeets, D., Székely, B., Larsimont, D., Szász, A. M., Adnet, P.-Y., Rothé, F., Rouas, G., Nagy, Z. I., Faragó, Z., et al. (2017) · Nature Communications · doi:10.1038/ncomms14944 · Cited by 178
Therapeutic resistance to anti-oestrogen therapy in breast cancer
Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00604-3 · Cited by 176
Brufsky, A. M., & Dickler, M. N. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0423 · Cited by 165
“In contrast, treatment with fulvestrant does not select for ESR1 mutations conferring constitutive activation of ERa [67].”
BackgroundInfluentialTurner, N. C., Swift, C., Kilburn, L., Fribbens, C., Beaney, M., Garcia-Murillas, I., Budzar, A. U., Robertson, J. F. R., Gradishar, W., Piccart, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0224 · Cited by 160
“S6), this analysis is limited by small numbers, and other datasets have not shown improved outcome of polyclonal versus monoclonal on fulvestrant (18).”
ResultSelf-citationBihani, T., Patel, H. K., Arlt, H., Tao, N., Jiang, H., Brown, J. L., Purandare, D. M., Hattersley, G., & Garner, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2561 · Cited by 161
“Recent clinical data have demonstrated that while the presence of ESR1mutations can be a prognostic indicator of AI resistance, the extent of fulvestrant efficacy is not influenced by ESR1 status (32, 33), suggesting SERDs have therapeutic value in this clinical context.”
BackgroundGenomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0013-8 · Cited by 166
“11 ctDNA assessment has also been used to identify presence of multiple concurrent tumor resistance mechanisms, study clonal evolution with treatment, 12 and provide early detection of new mutations even prior to gross tumor growth.”
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Razavi, P., Dickler, M. N., Shah, P. D., Toy, W., Brown, D. N., Won, H. H., Li, B. T., Shen, R., Vasan, N., Modi, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0047-1 · Cited by 159
Bahreini, A., Li, Z., Wang, P., Levine, K. M., Tasdemir, N., Cao, L., Weir, H. M., Puhalla, S. L., Davidson, N. E., Stern, A. M., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0851-4 · Cited by 160
“This is further supported by retrospective analysis of clinical trial samples, recently reported in two independent studies [26, 27].”
BackgroundResultStructural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes
Yu, X., Yi, P., Hamilton, R. A., Shen, H., Chen, M., Foulds, C. E., Mancini, M. A., Ludtke, S. J., Wang, Z., & O’Malley, B. W. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.031 · Cited by 154
Self-citationPathways to Endocrine Therapy Resistance in Breast Cancer
Haque, M. M., & Desai, K. V. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00573 · Cited by 161
“Some mutations in ER lead to hypersensitivity to circulating estrogen and make ER highly active such that tumors do not respond well to Tam therapy (33).”
BackgroundSeoane, J., De Mattos-Arruda, L., Le Rhun, E., Bardelli, A., & Weller, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy544 · Cited by 144
Cell-Free DNA: Hope and Potential Application in Cancer
Yan, Y., Guo, Q., Wang, F., Adhikari, R., Zhu, Z.-Y., Zhang, H., Zhou, W., Yu, H., Li, J., & Zhang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.639233 · Cited by 150
“The presence of ESR1 mutation indicates the development of endocrine resistance, especially resistant to aromatase inhibitors (Spoerke et al., 2016).”
BackgroundOvercoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer
Al-Fakeeh, A., & Brezden‐Masley, C. (2018) · Current Oncology · doi:10.3747/co.25.3752 · Cited by 140
Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V. M., Ericsson, P. I. G., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7993 · Cited by 136
“It is less clear whether they are associated with resistance to SERDs like fulvestrant or SERMs like tamoxifen (42).”
BackgroundLiquid Biopsy in Breast Cancer: A Focused Review
Tay, T. K. Y., & Tan, P. H. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0559-ra · Cited by 133
Lloyd, M. R., Wander, S. A., Hamilton, E., Razavi, P., & Bardia, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113694 · Cited by 109
Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., et al. (2016) · eLife · doi:10.7554/elife.15828 · Cited by 118
“These data are consistent with recent retrospective clinical studies showing that ESR1 mutations in plasma DNA predict relative resistance to AIs but not to fulvestrant (Fribbens et al., 2016; Schiavon et al., 2015; Spoerke et al., 2016).”
Self-citationTolaney, S. M., Toi, M., Neven, P., Sohn, J., Grischke, E.-M., Llombart‐Cussac, A., Soliman, H., Wang, H., Wijayawardana, S. R., Jansen, V. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3276 · Cited by 128
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Buono, G., Gerratana, L., Bulfoni, M., Provinciali, N., Basile, D., Giuliano, M., Corvaja, C., Arpino, G., Mastro, L. D., Placido, S. D., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.01.004 · Cited by 124
Zundelevich, A., Dadiani, M., Kahana‐Edwin, S., Itay, A., Sella, T., Gadot, M., Cesarkas, K., Barhom, S. F., Saar, E. G., Eyal, E., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-1246-5 · Cited by 132
Kwan, T. T., Bardia, A., Spring, L. M., Giobbie‐Hurder, A., Kalinich, M., Dubash, T. D., Sundaresan, T. K., Hong, X., LiCausi, J. A., Ho, U. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0432 · Cited by 114
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
Jeselsohn, R. M., Angelis, C. D., Brown, M. A., & Schiff, R. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0591-8 · Cited by 120
Paoletti, C., Cani, A. K., Larios, J. M., Hovelson, D. H., Aung, K., Darga, E. P., Cannell, E. M., Baratta, P. J., Liu, C., Chu, D. T. W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2686 · Cited by 112
Tellez-Gabriel, M., Knutsen, E., & Perander, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249457 · Cited by 114
Bardia, A., Kaklamani, V., Wilks, S., Weise, A., Richards, D., Harb, W., Osborne, C., Wesolowski, R., Karuturi, M., Conkling, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02272 · Cited by 105
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 115
Clatot, F., Perdrix, A., Augusto, L., Beaussire, L., Delacour, J., Calbrix, C., Sefrioui, D., Viailly, P., Bubenheim, M., Moldovan, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12950 · Cited by 106
“Similar results have recently been reported by Spoerke who suggested that all metastatic lesions may not harbour ESR1 mutations and may have different responses to post-AI treatment [11].”
BackgroundResultInfluentialAngus, L., Beije, N., Jager, A., Martens, J. W. M., & Sleijfer, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.001 · Cited by 102
“In the randomized phase II FERGI trial, baseline plasma samples of patients failing to AI treatment randomized either to fulvestrant combined with the pan-PI3K inhibitor pictilisib or to the combination of fulvestrant and placebo, were examined for ESR1 and PIK3CA mutations in tissue and cfDNA using BEAMing [36].”
InfluentialClinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
Reinert, T., Saad, E. D., Barrios, C. H., & Bines, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00026 · Cited by 98
“ESR1 mutations are generally clustered between amino acids 534–538, though mutations at other positions, including S463 and E380, have also been described (1, 2, 25).”
BackgroundESR1 alterations and metastasis in estrogen receptor positive breast cancer
Lei, J. T., Gou, X., Şeker, S., & Ellis, M. J. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.12 · Cited by 117
“Although formalin-fixed paraffin-embedded tumor specimens are widely used for next generation sequencing to capture ESR1 mutations used by studies as described above([37,53,54]), collection of plasma circulating DNA to detect ESR1 mutations by droplet digital PCR (ddPCR) have now been implemented in several clinical t…”
MethodXi, J., Oza, A., Thomas, S. N., Ademuyiwa, F. O., Weilbaecher, K. N., Suresh, R., Bose, R., Cherian, M. A., Hernandez-Aya, L. F., Frith, A. E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7094 · Cited by 95
Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution
Venkatesan, S., Swanton, C., Taylor, B. S., & Costello, J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026617 · Cited by 106
“Parallel and convergent cancer evolution, the phenomenon of different subclones originating from the same or different cancer-initiating cells acquiring genetic aberrations in similar pathways, lend support to the concept of pathway dependency (Misale et al. 2014; Shi et al. 2014; Juric et al. 2015; Pagliarini et al.…”
BackgroundChen, X., Chang, C., Spoerke, J. M., Yoh, K. E., Kapoor, V., Baudo, C. D., Aimi, J., Yu, M., Liang-Chu, M. M. Y., Suttmann, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1593 · Cited by 94
“Next, to determine the feasibility of LP-WGS to detect CNVs in cfDNA samples from patients with cancer, we validated the assay using cfDNA from 12 patients with metastatic breast cancer enrolled in the FERGI trial (27) where the copy number status for 35 genes in tumor tissue, which were not contemporaneously collecte…”
MethodSelf-citationHamilton, E. P., Patel, M. R., Armstrong, A. C., Baird, R. D., Jhaveri, K. L., Hoch, M., Klinowska, T. C. M., Lindemann, J. P. O., Morgan, S. R., Schiavon, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3102 · Cited by 89
“Indeed, although ESR1 mutations appear to predict resistance to aromatase inhibitor therapy, such mutations do not appear to influence outcomes in patients treated with fulvestrant (13).”
BackgroundSelli, Ç., Dixon, J. M., & Sims, A. H. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0779-0 · Cited by 98
“However, in a recent retrospective study, serial analysis of ctDNA did not show any evidence for accumulation of ESR1 mutations during fulvestrant treatment, and progression-free survival was not different in patients with ESR1 mutations [73].”
BackgroundChung, J., Pavlick, D. C., Hartmaier, R. J., Schrock, A. B., Young, L., Forcier, B., Ye, P., Levin, M. K., Goldberg, M. E., Burris, H. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx490 · Cited by 87
“Consistent with other studies, we frequently observed cases harboring>1 ESR1 GA [9, 10].”
BackgroundResultInfluentialTolaney, S. M., Chan, A., Petráková, K., Delaloge, S., Campone, M., Iwata, H., Peddi, P. F., Kaufman, P. A., de Kermadec, E., Liu, Q., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02746 · Cited by 90
“This, in turn,mayaffect theextent of thedifference in responsebetweenoralSERDsandETSOCand help explain conflicting results reported for response to fulvestrant in patients with mESR1.(14,25,31,32) In AMEERA-3, patients with the ESR1-Y537Smutation had numerically longer PFS with amcenestrant versus TPC, suggesting that…”
ResultHotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
Li, Z., Wu, Y. F., Yates, M. E., Tasdemir, N., Bahreini, A., Chen, J., Levine, K. M., Priedigkeit, N., Nasrazadani, A., Ali, S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2576 · Cited by 87
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Lloyd, M. R., Jhaveri, K. L., Kalinsky, K. M., Bardia, A., & Wander, S. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00935-6 · Cited by 97
Santo, I. D., McCartney, A., Migliaccio, I., Leo, A. D., & Malorni, L. (2019) · Cancers · doi:10.3390/cancers11121894 · Cited by 83
“However, this analysis did not demonstrate an association between the presence of ESR1 mutations and clinical outcome [51].”
ESR1 mutations: a new biomarker in breast cancer
Carausu, M., Bidard, F., Callens, C., Melaabi, S., Jeannot, E., Pierga, J., & Cabel, L. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1631799 · Cited by 79
“As of January 2019, 1,015 patients with ER+ HER2- MBC had been included.”
BackgroundInfluentialEstrogen receptor-α signaling in post-natal mammary development and breast cancers
Rusidzé, M., Adlanmérini, M., Chantalat, É., Raymond‐Letron, I., Cayre, S., Arnal, J., Deugnier, M., & Lenfant, F. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03860-4 · Cited by 82
Ballinger, T. J., Meier, J. B., & Jansen, V. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00308 · Cited by 82
Zhang, L., Liang, Y., Li, S., Zeng, F., Meng, Y., Chen, Z., Liu, S., Tao, Y., & Yu, F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0989-z · Cited by 73
“Similar cases have also been reported in myeloma [167, 168], NSCLC [169], breast cancer [170], and colon cancer, among others.”
ResultLoss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin
Gao, Y., Wang, Z., Hao, Q., Li, W., Xu, Y., Zhang, J., Zhang, W., Wang, S., Liu, S., Li, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14483 · Cited by 76
Hu, Z.-Y., Xie, N., Tian, C., Yang, X., Liu, L., Li, J., Xiao, H., Wu, H., Lü, J., Gao, J., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.015 · Cited by 79
“[20] Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, et al.”
BackgroundDownton, T. D., Zhou, F. H., Segara, D., Jeselsohn, R. M., & Lim, E. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s380925 · Cited by 77
“ESR1 mutations are rare de novo but may be selected for by AI therapy with prevalence of up to 40% in advanced breast cancer patients who have progressed on this treatment.(22,27) Fulvestrant has activity in vitro against breast cancer cells with mutant ERα, though the extent of inhibition of mutant ERα is less than t…”
BackgroundInfluentialESR1 activating mutations: From structure to clinical application
Grinshpun, A., Chen, V. C., Sandusky, Z. M., Fanning, S. W., & Jeselsohn, R. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188830 · Cited by 88
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
Venetis, K., Pepe, F., Pescia, C., Cursano, G., Criscitiello, C., Frascarelli, C., Mane, E., Russo, G., Salimbeni, B. T., Troncone, G., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102642 · Cited by 75
Wang, R., Li, X., Zhang, H., Wang, K., & He, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20608 · Cited by 68
“Researchers assayed hotspot mutations in ESR1 and PIK3CA from ctDNA in clinical trial samples from ER positive metastatic breast cancer patients, and finally made the conclusion that ESR1 mutation allele frequency does not show a consistent pattern of increases during fulvestrant treatment, and progression-free surviv…”
ResultPavlin, M., Spinello, A., Pennati, M., Zaffaroni, N., Gobbi, S., Bisi, A., Colombo, G., & Magistrato, A. (2018) · Scientific Reports · doi:10.1038/s41598-017-17364-4 · Cited by 71
Paoletti, C., Schiavon, G., Dolce, E. M., Darga, E. P., Carr, T. H., Geradts, J., Hoch, M., Klinowska, T., Lindemann, J., Marshall, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1569 · Cited by 62
“However, pre-clinical and independent exploratory clinical studies have suggested that patients with ESR1LBDm have shorter progression free survival (PFS) on subsequent AI therapy vs patients with ESR1LBD wildtype (WT) cancers and yet may retain relative (possibly dose-dependent) sensitivity to fulvestrant (5, 9-12).”
BackgroundCampone, M., Im, S., Iwata, H., Clemons, M. J., Ito, Y., Awada, A. H., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.002 · Cited by 66
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis
Bado, I., Gugala, Z., Fuqua, S. A. W., & Zhang, X. (2017) · Oncogene · doi:10.1038/onc.2017.94 · Cited by 71
Clusan, L., Goff, P. L., Flouriot, G., & Pakdel, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020756 · Cited by 69
“The most prevalent ERα mutation is a substitution of the amino acid Y537 in S, N or C (a Y537D mutation was also observed in one patient) with a prevalence reaching 60% of mutations detected in metastatic breast cancer samples [29,31].”
BackgroundRej, R. K., Roy, J., & Allu, S. R. (2024) · Cancers · doi:10.3390/cancers16030552 · Cited by 70
“Recent research indicates a potential link between the PI3K/AKT/mTOR pathway and acquired resistance to endocrine therapy in HR+ breast cancer.”
BackgroundGates, L. A., Gu, G., Chen, Y., Rohira, A. D., Lei, J. T., Hamilton, R. A., Yu, Y., Lonard, D. M., Wang, J., Wang, S.-P., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0284-2 · Cited by 62
Beije, N., Sieuwerts, A. M., Kraan, J., Van, N. M., Onstenk, W., Vitale, S. R., van der Vlugt‐Daane, M., Dirix, L. Y., Brouwer, A., Hamberg, P., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12147 · Cited by 62
“…ESR1 mutations were observed after progression on fulvestrant, suggesting that although it has been reported that fulvestrant is more effective than AIs in ESR1-mutant patients (Fribbens et al., 2016; Spoerke et al., 2016), mutant subclones can still be observed at PD on fulvestrant therapy.”
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Tomiguchi, M., Sueta, A., Murakami, K., Omoto, Y., & Iwase, H. (2017) · Oncotarget · doi:10.18632/oncotarget.18479 · Cited by 66
“On the other hand, Spoerkle and colleagues did not show clinical utility of ESR1 mutations as a monitoring tool [24].”
BackgroundZundelevich, A., Dadiani, M., Kahana‐Edwin, S., Itay, A., Sella, T., Gadot, M., Cesarkas, K., Barhom, S. F., Saar, E. G., Eyal, E., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01265-y · Cited by 61
Zhao, Y., Laws, M. J., Guillen, V. S., Ziegler, Y., Min, J., Sharma, A., Kim, S. H., Chu, D. T. W., Park, B. H., Oesterreich, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1265 · Cited by 63
“These ER mutations are all in the ligand binding domain of the receptor, and most frequently they result in changes at amino acid Y537 or D538 to generate Y537S (or N) or D538G constitutively active receptors (18,19).”
Dickinson, K., Sharma, A., Agnihotram, R. V., Altuntur, S., Park, M., Meterissian, S. H., & Burnier, J. V. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.31722 · Cited by 63
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer
Pejerrey, S. M., Dustin, D. J., Kim, J.-A., Gu, G., Rechoum, Y., & Fuqua, S. A. W. (2018) · Hormones and Cancer · doi:10.1007/s12672-017-0306-5 · Cited by 64
Mao, C., Livezey, M. R., Kim, J. E., & Shapiro, D. J. (2016) · Scientific Reports · doi:10.1038/srep34753 · Cited by 64
“Although the mutations exhibit an altered ER α conformation 5 , and are close to the proposed BHPI binding site 21 , BHPI was as effective in blocking proliferation of all 14 of the ER α Y537S and ER α D538G cell lines as it was in T47D cells.”
Allouchery, V., Beaussire, L., Perdrix, A., Sefrioui, D., Augusto, L., Guillemet, C., Sarafan‐Vasseur, N., Fiore, F. D., & Clatot, F. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0968-0 · Cited by 56
“Second, since we focused the analysis on the four main ESR1 mutations, we cannot exclude the presence of rare circulating mutations [10].”
New insights into acquired endocrine resistance of breast cancer
Fan, P., & Jordan, V. C. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.13 · Cited by 63
“Of note, ERα mutations are also enriched in PI3KCA mutant tumors and most of these point mutations are ERα phosphorylation sites[69].”
BackgroundThe genomic landscape of metastatic breast cancer: Insights from 11,000 tumors
Rinaldi, J., Sokol, E. S., Hartmaier, R. J., Trabucco, S. E., Frampton, G. M., Goldberg, M. E., Albacker, L. A., Daemen, A., & Manning, G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231999 · Cited by 65
Miranda, F., Prazeres, H., Mendes, F., Martins, D. F., & Schmitt, F. C. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06863-3 · Cited by 57
Parsons, H. A., Beaver, J. A., Cimino‐Mathews, A., Ali, S. M., Axilbund, J. E., Chu, D. T. W., Connolly, R. M., Cochran, R. L., Croessmann, S., Clark, T. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1543 · Cited by 58
“For example, recent findings suggest that ESR1 (estrogen receptoralpha) ligand binding domainmutations occur predominantly, if not exclusively, in metastatic breast cancer patients after endocrine therapies (22–24), and that ptDNA can detect additional mutations not found in tissue biopsies (13, 25, 26).”
BackgroundMolecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
Freelander, A., Brown, L. J., Parker, A. J., Segara, D., Portman, N., Lau, B., & Lim, E. (2021) · Genes · doi:10.3390/genes12020285 · Cited by 62
Zhang, K., Hong, R., Xu, F., Xia, W., Lee, K., Qin, G., Zheng, Q., Lu, Q., Shi, Y. X., Yuan, Z. Y., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s173193 · Cited by 50
“19–23 However, consensus has not been reached regarding the reliability of ESR1 mutations in cfDNA/ctDNA as predictive biomarkers due to some limitations with the current evidence.”
Berger, F., Marce, M., Delaloge, S., Bessard, A. C. H., Bachelot, T., Bièche, I., Pradines, A., Rouge, T. D. L. M., Canon, J.-L. R., André, F., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055821 · Cited by 57
Kuang, Y., Siddiqui, B. A., Hu, J., Pun, M. J., Cornwell, M., Buchwalter, G., Hughes, M. E., Wagle, N., Kirschmeier, P. T., Janne, P. A., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0075-5 · Cited by 50
Self-citationJhaveri, K. L., & Marmé, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102670 · Cited by 56
Najim, O., Seghers, S., Sergoynne, L., Gaver, H. V., Papadimitriou, K., Wouters, K., Trinh, X. B., Huizing, M. T., & Tjalma, W. A. A. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188315 · Cited by 48
The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy
Cummings, C., Peters, E. J., Lacroix, L., André, F., & Lackner, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12429 · Cited by 49
Self-citationKutasovic, J. R., Reed, A. E. M., Males, R., Sim, S., Saunus, J. M., Dalley, A. J., McEvoy, C. R. E., Dedina, L., Miller, G. C., Peyton, S., et al. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.118 · Cited by 50
“Detecting mutant ESR1 in circulating DNA may therefore prove to be an important biomarker of relapse [54,55], though heterogeneity between metastases in the same patient may be confounding.”
BackgroundKhan, A., Rehman, A. U., Junaid, M., Li, C.-D., Saleem, S., Humayun, F., Shamas, S., Ali, S. S., Babar, Z., & Wei, D. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00159 · Cited by 52
Gornstein, E. L., Sandefur, S., Chung, J., Gay, L. M., Holmes, O., Erlich, R., Soman, S., Martin, L.-A., Rose, A. V., Stephens, P. J., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.12.010 · Cited by 49
Personalizing aromatase inhibitor therapy in patients with breast cancer
Hamadeh, I. S., Patel, J. N., Rusin, S., & Tan, A. R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.014 · Cited by 46
Metadata
- Authors
- Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., Amler, L. C., Hampton, G. M., Johnston, S., Krop, I., Schmid, P., & Lackner, M. R.
- Affiliations
- Genentech (US)
- Royal Marsden NHS Foundation Trust (GB)
- Dana-Farber Cancer Institute (US)
- Queen Mary University of London (GB)
- Corresponding author
- Lackner, Mark R.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-05-13
- Volume
- 7
- Issue
- 1
- Pages
- 11579-11579
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4869259
- OpenAlex
- W2374277491
- Cited by
- 309
- References
- 41
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 14 · 2023: 30 · 2022: 27 · 2021: 37 · 2020: 28 · 2019: 42 · 2018: 36 · 2017: 41 · 2016: 12
- FWCI
- 39.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Research UK
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- ESR1 mutations, fulvestrant, PIK3CA mutation, circulating tumor DNA, clonal evolution, treatment resistance, pan-PI3K inhibitor, progression-free survival, luminal A
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast, Breast Neoplasms, DNA Mutational Analysis, DNA, Neoplasm, Estradiol, Estrogens, Female, Humans, Indazoles, Middle Aged, Mutation, Sulfonamides, Disease-Free Survival, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Estrogen Receptor alpha, Class I Phosphatidylinositol 3-Kinases, Estrogen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.